Wire · opportunities
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The FDA has placed a second clinical hold this year on Regenxbio's gene therapy for Hunter syndrome after detecting safety concerns involving spinal masses in five patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 24 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
Gene therapy founders focused on rare diseases must treat FDA holds as urgent access blockers and adjust trial safety protocols immediately. This pause signals tightening FDA scrutiny that could delay market entry and increase development costs.
◆ Coverage
3 sources · first reported 24 Aug 2026 · latest 31 Aug 2026
◆ Related on Wire
◆ Topics